drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-engineered T cells)
drug_description
Autologous, gene-modified TCR T-cell therapy engineered to express an HLA-A*02:01–restricted TCR recognizing HPV16/52 antigens; mediates antigen-specific cytotoxicity and cytokine release against HPV-positive tumor cells; administered after lymphodepletion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express an HLA-A*02:01–restricted TCR that recognizes HPV16/52-derived peptides on tumor cells; antigen/MHC engagement activates the T cells to release cytotoxic granules and cytokines, mediating targeted killing of HPV-positive tumor cells. Administered after lymphodepletion to promote expansion and persistence.
drug_name
SCG142
nct_id_drug_ref
NCT06505551